Progress in Development and Application of Decision-making Systems for Individualized Dosing
LIU Xiao-qin1,2, JIAO Zheng1*, GAO Yu-cheng1, ZHENG Xin-yi1,2, HUANG Hong3
1. Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai 200040, China; 2. School of Pharmacy, Fudan University, Shanghai 201203, China; 3. Department of Medical Information, Huashan Hospital, Fudan University, Shanghai 200040, China
Abstract��With the progress of dose individualization theory and research, decision-making systems have increasingly emerged in recent years. In this paper, common individualized dosing computer program, web platform and application on mobile devices are identified and summarized by searching literatures and internet, and compared with each other in terms of general characteristics and professional characteristics. Twenty-five systems are included in total. These systems, which estimate parameters mostly by Bayesian algorithm, cover anti-bacterial drugs and antiviral drugs, immunosuppressants, anti-tumor drugs, nervous system drugs, cardiovascular system drugs, respiratory system drugs and so on. MwPharm++, a commercial computer program, has the best comprehensive performance among all these. Besides, highlighted advantages are showed in commercial computer program Precise PK, APK, free computer program JPKD, BestDose and web platform SmartDose. Along with the development of internet and the high performance computing tools, mobile apps are booming. It is expected that the decision-making systems to be developed and promoted continuously in the future and could provide more options and references for clinical individualized dosing.
������, ����, �����, ֣����, �ƺ�. ���廯��ҩ��������ϵͳ�о���Ӧ�ý�չ[J]. �й�ҩѧ��־, 2019, 54(1): 1-8.
LIU Xiao-qin, JIAO Zheng, GAO Yu-cheng, ZHENG Xin-yi, HUANG Hong. Progress in Development and Application of Decision-making Systems for Individualized Dosing. Chinese Pharmaceutical Journal, 2019, 54(1): 1-8.
LING J, JIAO Z, ZHONG M K. Overviews and advances in studies of target concentration intervention [J]. Chin Pharm J(�й�ҩѧ��־), 2013, 48(16):1337-1342.
[2]
HAMBERG A K, HELLMAN J, DAHLBERG J, et al. A Bayesian decision support tool for efficient dose individualization of warfarin in adults and children [J]. BMC Med Inform Decis Mak, 2015,15(7):1-9.
[3]
GAO Y C, JIAO Z, HUANG H, et al. Development of decision system for individualization of vancomycin dosage [J]. Acta Pharm Sin(ҩѧѧ��), 2018, 53(1):104-110.
[4]
BUFFINGTON D E, LAMPASONA V, CHANDLER M H. Computers in pharmacokinetics: choosing software for clinical decision making [J]. Clin Pharmacokinet, 1993, 25(3):205-216.
[5]
FUCHS A, CSAJKA C, THOMA Y, et al. Benchmarking therapeutic drug monitoring software: a review of available computer tools [J]. Clin Pharmacokinet, 2013, 52(1):9-22.
[6]
FU S S, DUAN J L. Progress in application of therapeutic drug monitoring softwares [J]. Chin J Clin Pharmacol(�й��ٴ�ҩ��ѧ��־), 2012, 28(9):701-703, 713.
[7]
GAGE B F, EBY C, JOHNSON J A, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin [J]. Clin Pharmacol Ther, 2008, 84(3):326-331.
[8]
PROOST J H, MEIJER D K. MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring [J]. Comput Biol Med, 1992, 22(3):155-163.
[9]
JELLIFFE R W, NEELY M. Individualized Drug Therapy for Patients: Basic Foundations, Relevant Software and Clinical Applications[M]. Netherlands: Elsevier, 2016.
[10]
JELLIFFE R W. The USC*PACK PC programs for population pharmacokinetic modeling, modeling of large kinetic/dynamic systems, and adaptive control of drug dosage regimens [J]. Proc Annu Symp Comput Appl Med Care, 1991:922-924.
DOSEME. Drug packages[EB/OL]. Australia: DoseMe [2018-03-31]. https://doseme-rx.com/our-platform#drug_packages.
[13]
WORRALL S P, ALMOND M K, DHILLON S. Pharmacokinetics of bupropion and its metabolites in haemodialysis patients who smoke. A single dose study [J]. Nephron Clin Pract, 2004, 97(3):83-89.
[14]
PULLEN J, DE ROZARIO L, STOLK L M, et al. Population pharmacokinetics and dosing of flucloxacillin in preterm and term neonates [J]. Ther Drug Monit, 2006, 28(3):351-358.
[15]
KERKHOFS T M, DERIJKS L J, ETTAIEB H, et al. Development of a pharmacokinetic model of mitotane: toward personalized dosing in adrenocortical carcinoma [J]. Ther Drug Monit, 2015, 37(1):58-65.
[16]
WRIGHT D F, DUFFULL S B. Development of a bayesian forecasting method for warfarin dose individualization [J]. Pharm Res, 2011, 28(5):1100-1111.
[17]
DENG C H, ZHANG G M, BI S S, et al. The therapeutic drug monitoring network server of tacrolimus for Chinese renal transplant patients [J]. Acta Pharm Sin(ҩѧѧ��), 2011, 46(7):828-833.
[18]
YIN Y Q, LIN W W, JIAO Z, et al. Development of software for individualized dosage regimen of valproic acid and carbamazepine [J]. Chin Pharm J(�й�ҩѧ��־), 2014, 49(2):163-166.
[19]
HOPE W W, VANGUILDER M, DONNELLY J P, et al. Software for dosage individualization of voriconazole for immunocompromised patients [J]. Antimicrob Agents Chemother, 2013, 57(4):1888-1894.
[20]
FELTON T W, ROBERTS J A, LODISE T P, et al. Individualization of piperacillin dosing for critically �� patients: dosing software to optimize antimicrobial therapy [J]. Antimicrob Agents Chemother, 2014, 58(7):4094-4102.
[21]
NEELY M N, KATO L, YOUN G, et al. Prospective trial on the use of trough concentration versus area under the curve to determine therapeutic vancomycin dosing [J]. Antimicrob Agents Chemother, 2018, 62(2):e02042-17.
[22]
MAREK E, MOMPER J D, HINES R N, et al. Prediction of warfarin dose in pediatric patients: an pvaluation of the predictive performance of several models [J]. J Pediatr Pharmacol Ther, 2016, 21(3):224-232.
[23]
LIU Y, YANG J, XU Q, et al. Comparative performance of warfarin pharmacogenetic algorithms in Chinese patients [J]. Thromb Res, 2012, 130(3):435-440.
[24]
CHUMNUMWAT S, YI K, LUCKSIRI A, et al. Comparative performance of pharmacogenetics-based warfarin dosing algorithms derived from Caucasian, Asian, and mixed races in Thai population [J]. Cardiovasc Ther, 2018, 36(2):e12315.
[25]
STORSET E, ASBERG A, SKAUBY M, et al. Improved tacrolimus target concentration achievement using computerized dosing in renal transplant recipients-a prospective, randomized study [J]. Transplantation, 2015, 99(10):2158-2166.
[26]
MOULD D R, D��HAENS G, UPTON R N. Clinical decision support tools: the evolution of a revolution [J]. Clin Pharmacol Ther, 2016, 99(4):405-418.
[27]
DARWICH A S, OGUNGBENRO K, VINKS A A, et al. Why has model-informed precision dosing not yet become common clinical reality? Lessons from the past and a roadmap for the future [J]. Clin Pharmacol Ther, 2017, 101(5):646-656.
[28]
ZHAO C Y, JIAO Z, MAO J J, et al. External evaluation of published population pharmacokinetic models of tacrolimus in adult renal transplant recipients [J]. Br J Clin Pharmacol, 2016, 81(5):891-907.
[29]
MAO J J, JIAO Z, YUN H Y, et al. External evaluation of population pharmacokinetic models for ciclosporin in adult renal transplant recipients [J]. Br J Clin Pharmacol, 2018, 84(1):153-171.
[30]
DENG C, LIU T, WU K, et al. Predictive performance of reported population pharmacokinetic models of vancomycin in Chinese adult patients [J]. J Clin Pharm Ther, 2013, 38(6):480-489.
[31]
JIAO Z. The use of softwares for individualized dosing[EB/OL]. Community of clinical pharmacy, 2018 [2018-05-31]. http://www.linyaoquan.com/kecheng/detail_1557553?f=org_coursecenter.
2019, Vol. 54 
